Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Monotherapy in Previously Treated Advanced NSCLC (Non-HBV-Infected)
CTR20171020Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Sep 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20171020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171020.